Molecule to Medicine: How Daraxonrasib is Rewriting Pancreatic Cancer Drug Development
Monash University’s Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a 500‑patient phase 3 trial for previously treated metastatic pancreatic cancer (RASolute 302; NEJM, May 31, 2026). Developed from an academic spinout and advanced through acquisition and optimization, […]
Molecule to Medicine: How Daraxonrasib is Rewriting Pancreatic Cancer Drug Development Read More »
